Key Summary Points {#FPar1}
==================

Obesity is a complex metabolic disorder, with several licensed drug and surgical therapies currently available.Current therapies are often associated with inadequate efficacy or complications and side effects, limiting their use.Multiple pathophysiological mechanisms of obesity are recognized, though only few of these are manipulated using currently licensed therapies.Whilst most drug classes are in early stages of development and/or clinical trials, results are promising for multiple drug targets.

Introduction {#Sec1}
============

Obesity is the modern epidemic, generally defined as a body mass index (BMI) ≥ 30 kg/m^2^, though a BMI ≥ 27.5 kg/m^2^ defines obesity in Asian populations \[[@CR1]\]. Currently, 28.7% of people in England are obese with a further 35.6% overweight \[[@CR2]\]. Worryingly, the worldwide prevalence of obesity continues to increase and has tripled since 1975, with 1.6 billion overweight adults and 650 million obese adults \[[@CR3]\]. Obesity comes with both significant economic and personal costs. One American-based study estimated the additional annual cost associated with obesity in men was US \$1152 and in women was US \$3613, which given the high prevalence of obesity in the US led to an estimated spending of about \$190 billion per year (21% of total healthcare spending) \[[@CR4]\]. In the UK, the estimated spend on obesity in 2014/15 was £6.1 billion and is projected to reach £9.7 billion by 2050, with an estimated societal cost of almost £50 billion \[[@CR5]\]. Whilst the economic cost of obesity is substantial, the personal cost is often greater with an increased risk of multiple medical and mental health complications. Obesity is associated with increased all-cause mortality and contributed to more than 4 million deaths worldwide in 2015 \[[@CR6]\]. Cardiovascular disease accounted for 2.7 million deaths, whilst diabetes was the second leading cause at 0.9 million deaths. Although chronic kidney disease and obesity-associated cancer (hepatic, renal, breast, prostate and colon) each accounted for ≤ 10% of obesity-related deaths, these conditions are associated with major disability and poorer quality of life \[[@CR6]\].

There is growing interest in drug therapies that can support weight loss and thereby reduce the prevalence of obesity and obesity-related complications. Intensive lifestyle interventions for people with obesity are associated with significant improvements in weight, amongst other parameters. The Look AHEAD trial observed a 5% reduction in body weight was associated with sustained improvements in key cardiovascular risk factors such as blood pressure and lipid profile \[[@CR7]\]. As such, many regulatory bodies use a 5% total weight loss to determine whether a drug induces a meaningful weight loss. Whilst the US Food and Drug Administration (FDA) has approved five drug therapies to treat obesity (orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide), the European Medicines Agency (EMA) has approved only three drug therapies (orlistat, bupropion/naltrexone and liraglutide) \[[@CR8]\] at the time of writing. Should medical therapies fail to achieve adequate weight loss, bariatric surgery is a final option for some people. Generally, these therapies support weight loss by either enhancing satiety, inhibiting hunger or increasing catabolism. However, with our evolving understanding of the underlying pathophysiology of obesity there are an increasing number of drug targets being identified, and it is anticipated that more medications will be approved by regulatory bodies such as the FDA and EMA to tackle the obesity epidemic.

In this article, we discuss the clinical trials investigating pharmacotherapy for people with obesity. However, we do not discuss real-world clinical data related to use of these drugs. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Summarises the mechanism of action for each class of pharmacotherapy used to treat obesity

Efficacy of Currently Approved Therapies for Obesity {#Sec2}
====================================================

Orlistat {#Sec3}
--------

Orlistat is a selective inhibitor of pancreatic lipase, which thereby moderates the intestinal digestion and absorption of fat, approved for use by both the FDA and EMA. It should be taken with meals and is available both by prescription and over the counter in lower doses in the UK \[[@CR9]\]. Orlistat is indicated for patients with a BMI ≥ 30 kg/m^2^ or ≥ 28 kg/m^2^ in association with other risk factors (e.g., hypertension, diabetes, hyperlipidaemia) \[[@CR10]\]. Whilst people with obesity using orlistat lose an extra 2.9--3.4 kg weight over 12 months, gastrointestinal side effects, reduced absorption of fat-soluble vitamins and steatorrhea are commonplace \[[@CR9]\]. Indeed, a recent systematic review observed a mean weight loss of 3.1 kg associated with orlistat use \[[@CR11]\]. Additional metabolic benefits associated with orlistat use include reduced blood pressure (systolic, 1.15 mmHg; diastolic, 1.07 mmHg) and reduced circulating lipids (total cholesterol, 0.30 mmol/l; low-density lipoprotein (LDL) cholesterol, 0.27 mmol/l; triglycerides, 0.09 mmol/l) \[[@CR12]\]. One study found the cost of weight loss per kilogram associated with orlistat was US\$546, with a cost of US\$71,000 per quality-adjusted life year (QALY) in Europe \[[@CR13]\].

Phentermine/Topiramate {#Sec4}
----------------------

Phentermine is a sympathomimetic that stimulates noradrenaline release suppressing appetite, whilst topiramate is an anticonvulsant that augments the weight loss associated with phentermine use though the mechanism of appetite suppression is unclear. It is an effective weight loss agent with studies observing 6.6--8.6 kg weight loss over 12 months \[[@CR9]\]. A more recent meta-analysis observed a mean weight loss of 9.8 kg associated with its use in randomised-controlled trials \[[@CR11]\]. However, side effects include insomnia, dizziness and paresthesia. Whilst approved by the FDA in 2012, as a result of safety concerns the EMA rejected the use of this therapy. Phentermine/topiramate use was found to cost US \$48,340 per QALY, a cost of US \$232/kg weight loss \[[@CR13], [@CR14]\].

Lorcaserin {#Sec5}
----------

Lorcaserin is as an appetite suppressant through activation of hypothalamic 5-HT~2C~ receptors and was approved for use by the FDA in 2012. It is used in people with BMI ≥ 30 kg/m^2^ or ≥ 27 kg/m^2^ with co-morbidity (e.g., hypertension, diabetes, dyslipidaemia) \[[@CR9]\]. The use of lorcaserin is associated with an additional annual weight loss of about 3.2--3.6 kg as well as improvements in metabolic parameters including blood pressure (systolic, 0.61 mmHg; diastolic, 0.49 mmHg) and lipids (total cholesterol, 0.35 mmol/l; LDL cholesterol, 0.35 mmol/l \[[@CR15]\]. A systematic review of randomised-controlled trials using locaserin noted a mean weight loss of 3.1 kg associated with its use \[[@CR11]\] Common side effects associated with lorcaserin use include headache, nausea and dizziness \[[@CR9], [@CR15]\]. Studies exploring this therapy report a cost of US\$545 per kilogram weight loss attained, with a cost of US\$122,640 per QALY gained \[[@CR13]\].

Naltrexone/Bupropion {#Sec06}
--------------------

Naltrexone is an opiate antagonist, whilst bupropion is a weak dopamine and noradrenaline reuptake inhibitor. It is approved for use by both the FDA and EMA in the treatment of obesity. In combination, these drugs promote satiety via enhancement of hypothalamic pro-opiomelanocortin (POMC) cell-mediated release of melanocyte-stimulating hormone (MSH) leading to reduced food intake and increased energy expenditure \[[@CR16]\]. Like other obesity pharmacotherapy, naltrexone/bupropion is indicated for BMI ≥ 30 kg/m^2^ or ≥ 27 kg/m^2^ in association with other obesity-related co-morbidities. An additional annual weight loss of 4.8% total body weight (mean 4.4 kg) has been observed, with side effects including nausea, headache and dizziness \[[@CR11], [@CR16]\].

Liraglutide {#Sec07}
-----------

Liraglutide is a glucagon-like peptide-1 (GLP-1) agonist, originally marketed for the treatment of type 2 diabetes (T2D). It is given as a once daily injection at a dose of 3.0 mg daily (compared with up to 1.8 mg daily for treatment of T2D) \[[@CR9]\]. Liraglutide improves weight loss by enhancing satiety via hypothalamic stimulation and delaying gastric emptying, thereby reducing food intake. It is approved by the FDA and EMA to support weight loss in people with BMI ≥ 30 kg/m^2^ or ≥ 27 kg/m^2^ and obesity-related co-morbidity \[[@CR9], [@CR17]\]. More common side effects include nausea/vomiting and pancreatitis. An additional annual weight loss of 5.3--5.9 kg has been observed compared with placebo \[[@CR11], [@CR17]--[@CR19]\].

The approved pharmacotherapies for weight loss in people with obesity are presented in Table [1](#Tab1){ref-type="table"}.Table 1A comparison of approved weight loss therapies in obesityDrugMechanism of actionDosingApproving bodiesWeight lossSide effectsOrlistatPancreatic lipase inhibitor60--120 mg three times dailyFDA (1999)EMA (1998)2.9--3.4 kg/yearSteatorrhea, faecal urgencyPhentermine/topiramateSympathomimetic, appetite suppressant3.75/23 mg; 7.5/46 mg; 11.25/69 mg; 15/92 mg once dailyFDA (2012)6.6--8.6 kg/yearInsomnia, dizziness, parasthesiaLorcaserin5-HT~2C~ receptor activation10 mg twice dailyFDA (2012)3.2--3.6 kg/yearHeadache, nausea, dizzinessNaltrexone/bupropionDopamine and noradrenaline reuptake inhibitor (bupropion); Opioid-receptor antagonist (naltrexone)32 mg/360 mg 2 tablets Four times dailyFDA (2014)EMA (2015)4.8% body weight per yearNausea/vomiting, headache, dizzinessLiraglutideGLP-1 receptor agonist3.0 mg injection once dailyFDA (2014) EMA (2015)5.9 kg/yearNausea, vomiting, pancreatitisCompares the mechanism or action, dosing, efficacy and more common side effects of already approved drug therapies used to support weight loss in obesity

Surgical Interventions {#Sec8}
======================

Several surgical interventions are approved in the treatment of obesity including devices (e.g., intragastric balloon, endoscopic sleeve gastroplasty, vagal nerve blockade, hydrogels) and surgery \[e.g., laparoscopic adjustable gastric banding (LAGB), roux-en-Y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD-DS)\]. Current UK guidelines recommend considering bariatric surgery in people with a BMI ≥ 40 kg/m^2^ or \> 35 kg/m^2^ with obesity-related co-morbidity \[[@CR20]\].

A recent meta-analysis observed that 6 months following bariatric surgery the mean difference in excess weight loss (%) versus the standard of care resulting from BPD-DS, RYGB and sleeve gastrectomy was 38.2%, 32.1% and 32.5%, respectively \[[@CR21]\]. Interestingly, LAGB was not superior to the standard of care. Importantly, diabetes remission rates were higher in participants who had undergone BPD-DS, RYGB or sleeve gastrectomy compared with the standard of care \[[@CR21]\]. Greater improvements has also been noted in several other metabolic parameters associated with bariatric surgery including blood pressure and lipids compared with medical treatment \[[@CR22]\]. Device therapies such as intragastric balloon, endoscopic sleeve gastroplasty or vagal nerve blockade are generally less effective weight loss strategies than surgical intervention, but provide 14--24% excess weight loss when used in the treatment of obesity \[[@CR23]\].

Nevertheless, concerns remain about complications in this group of patients who often pose very high surgical risk. Complications include anastomotic leak, anaesthetic complications, bleeding, band slippage or erosion, dumping syndrome, gallstone formation, hernia, luminal stenosis, vitamin deficiencies and venous thromboembolism \[[@CR24]\]. Avoiding surgical risks with newer drug therapies would represent major advances in obesity management and improve long-term outcomes for these patients.

Non-approved Therapies for Obesity {#Sec9}
==================================

Incretin-based Treatments {#Sec10}
-------------------------

Since the isolation of the peptide exendin-4 from *Heloderma suspectum* (Gila Monster) lizard venom in 1992 \[[@CR25]\], several drugs that manipulate the incretin axis have been produced and approved for use in people with T2D including exenatide (2005), liraglutide (2009), lixisenatide (2013), albiglutide (2014, withdrawn 2017), dulaglutide (2014) and semaglutide (2017) \[[@CR26]\]. The peptide GLP-1 is produced by the enteroendocrine L-cells of the small intestine as a cleavage product of the pre-proglucagon gene within minutes in response to oral glucose or fat. Concentrations are therefore much higher in the fed state, and these peptides are subsequently cleaved by dipeptidyl peptidase4 (DPP-4) enzymes rendering the GLP-1 peptide inactive \[[@CR26]\]. The first action of GLP-1 to be characterised was the stimulation of insulin and inhibition of glucagon release from the pancreatic islets \[[@CR27]\]. Therefore, this drug class controls dysglycaemia in people with T2D.

Importantly, GLP-1 receptors have been demonstrated in multiple organs throughout the body, including the pancreatic islets, gastrointestinal tract, kidney, lung, heart and centrally within the hypothalamus and pituitary \[[@CR28]\]. Therefore, GLP-1 analogues have been found to have several non-glycaemic effects including improved blood pressure through arterial vasodilation and increased renal natriuresis and reduced appetite via delayed gastric emptying and centrally mediated satiety within the hypothalamus. It is these latter actions that lead to reduced appetite and early satiety thereby contributing to weight loss in people who use GLP-1 analogues \[[@CR26]\]. Indeed, high-dose liraglutide (3.0 mg daily) is already approved to support weight loss in both Europe and the US. However, other GLP-1 analogues used either as monotherapy or in combination with other drug classes have the potential to encourage additional weight loss in people with obesity \[[@CR26]\], but are currently not licensed for this use and are licensed for use in T2D alone.

Whilst the use of DPP-4 inhibitors may theoretically support weight loss in the treatment of obesity through increasing the half-life of endogenous GLP-1, weight loss associated with their use is clinically insignificant (0.16--0.64 kg) \[[@CR29]\], and as such their use in obesity is not explored further in this manuscript.

GLP-1 Monotherapy {#Sec11}
-----------------

### Exenatide {#Sec12}

Exenatide (Byetta, Bydureon) was the first approved GLP-1 analogue in 2005, a synthetic form of the naturally occurring peptide exendin-4 first isolated from *Heloderma suspectum* (Gila Monster) lizard venom in 1992 \[[@CR25]\]. It is available either as a 10 mcg twice daily subcutaneous injection or as a 2 mg once weekly preparation. It is licensed for use in T2D as an add-on therapy to metformin, sulphonylureas, pioglitozone or long-acting insulin only. One systematic review reported that use of exenatide 20 mcg twice daily resulted in an additional 1.4 kg weight loss, whilst exenatide 2 mg once weekly was associated with 1.6 kg additional weight loss compared with placebo \[[@CR30]\].

### Liraglutide {#Sec13}

Liraglutide (Victoza) was approved for use in T2D in 2009 by the EMA at doses of up to 1.8 mg once daily subcutaneous injection for people with T2D as monotherapy in those unable to take metformin or as add-on treatment to oral agents and/or insulin. Subsequently, liraglutide (Saxenda) was approved in 2014 for the treatment of obesity up to a maximum dose of 3.0 mg subcutaneously once daily in people with a BMI ≥ 30 kg/m^2^, or ≥ 27 kg/m^2^ and obesity-related co-morbidity \[[@CR9], [@CR17]\]. Additional weight loss associated of 1.0 kg and 1.5 kg versus placebo with liraglutide of 1.2 mg and 1.8 mg is reported in one meta-analysis \[[@CR30]\]. Absolute weight loss with liraglutide 3.0 mg (Saxenda) is reported up to 5.9 kg over 56 weeks \[[@CR18], [@CR19]\].

### Lixisenatide {#Sec14}

The maximum recommended dose of lixisenatide (Lyxumia) is 20 mcg once daily via subcutaneous injection and is licensed for use in people with T2D as monotherapy in those who cannot take metformin or as an add-on treatment to oral agents and/or insulin \[[@CR31]\]. The use of lixisenatide was associated with up to 2 kg additional weight loss over 12 weeks compared with control in the GetGoal-Mono study \[[@CR32]\].

### Dulaglutide {#Sec15}

Dulaglutide (Trulicity) is administered subcutaneously at a maximum dose of 1.5 mg once weekly, and available on license since 2014 for people with T2D as monotherapy in those who cannot take metformin or as add-on treatment in people using oral agents and/or insulin. As monotherapy the use of dulaglutide in people with T2D has been reported to increase weight loss by up to 2.3 kg \[[@CR33]\]

### Semaglutide {#Sec16}

Semaglutide (Ozempic) is the most recent GLP-1 analogue to be approved for use in T2D and is currently available by subcutaneous injection for the treatment of T2D at a dose of up to 1.0 mg once weekly. It is licensed for use as monotherapy in those unable to take metformin or as add-on treatment. The absolute weight loss associated with semaglutide use is up to 4.6 kg and 6.5 kg at doses of 0.5 mg and 1.0 mg respectively over 40 weeks. Indeed, comparative trials have shown that semaglutide 1.0 mg demonstrated greater weight loss efficacy than dulaglutide 1.5 mg (6.5 kg vs. 3.0 kg) \[[@CR34]\]. Indeed, a phase II dose-finding trial demonstrated greater body weight reductions associated with daily subcutaneous semaglutide at a dose greater than 0.2 mg compared with liraglutide 3.0 mg daily \[[@CR35]\]. The development of oral semaglutide for T2D and/or obesity is of interest, as other GLP-1 analogues are currently available only as injectables often limiting their use. One trial recently reported that oral semaglutide (14 mg once daily) resulted in greater weight loss compared with subcutaneous liraglutide (4.4 kg vs. 3.1 kg) over 26 weeks \[[@CR36]\]. Whilst the FDA approved the use of oral semaglutide for the treatment of people with T2D in September 2019 \[[@CR37]\], the EMA have not approved its use in T2D at the time of writing.

The effect of currently approved GLP-1 monotherapies for T2D on weight loss are presented in Table [2](#Tab2){ref-type="table"}.Table 2GLP-1 monotherapy for obesityDrugLicensingMaximum recommended doseWeight lossExenatide \[[@CR28]\]Type 2 diabetes (FDA 2005; EMA 2006)10 mcg twice daily, or 2 mg once weekly10 mcg twice daily: 1.4 kg^a^2 mg once weekly: 1.6 kg^a^Liraglutide \[[@CR16], [@CR17], [@CR28]\]Type 2 diabetes (FDA 2010; EMA 2009); obesity (FDA 2014; EMA 2015)T2D: ≤ 1.8 mg once dailyObesity: ≤ 3.0 mg once daily1.8 mg once daily: 1.5 kg^a^3.0 mg once daily: 5.9 kg^a^Lixisenatide \[[@CR30]\]Type 2 diabetes (FDA 2016; EMA 2013)20 mcg once daily20 mcg daily: 2.0 kg^b^Dulaglutide \[[@CR31]\]Type 2 diabetes (FDA 2014; EMA 2014)1.5 mg once weekly1.5 mg weekly: 2.3 kg^b^0.75 mg weekly: 1.4 kg^b^Semaglutide \[[@CR32]\]Type 2 diabetes (FDA 2017; EMA 2018)1.0 mg once weekly1.0 mg weekly: 6.5 kg^b^0.5 mg weekly: 4.6 kg^b^Summarises the use and weight loss efficacy of available GLP-1 analogue monotherapy^a^Additional weight loss compared with control^b^Absolute weight loss

Multi-agonists {#Sec17}
==============

A single drug that acts at two or more different receptors may enhance weight loss compared with single receptor agonists and has the advantage of a single pharmacokinetic profile compared with multiple profiles observed with the co-administration of two or more drugs \[[@CR38]\]. This has led to the development and investigation of several incretin-related therapies such as unimolecular GLP-1/glucagon receptor dual agonists, GLP-1/gastric inhibitory polypeptide (GIP) dual agonists and GLP-1/GIP/glucagon receptor triple agonists. Whilst these multi-agonists have not yet been licensed for use in people with T2D and/or obesity, preclinical and early clinical trials support a future role for their use \[[@CR38]\].

GLP-1/Glucagon Receptor Dual Agonists {#Sec18}
-------------------------------------

The mechanism of GLP-1 receptor stimulation on satiety is discussed above. Glucagon receptor stimulation enhances energy expenditure by increasing oxygen consumption, lipid catabolism and thermogenesis amongst other factors \[[@CR39]\]. Oxyntomodulin is an endogenous peptide secreted by the enteroendocrine cells of the intestine in response to oral nutrients, which acts as an agonist at both GLP-1 and glucagon receptors \[[@CR40]\]. Indeed, the administration of oxyntomodulin reduces food intake and suppresses appetite \[[@CR41]\] by activation of GLP-1 receptors \[[@CR42]\] and increases energy expenditure via activation of the glucagon receptor \[[@CR43]\]. Thus, drugs that have a dual agonist effect at these receptors ought to potentiate weight loss.

Previous human trials have shown that subcutaneous administration of oxyntomodulin three times daily for 4 weeks resulted in 1.8 kg greater weight loss than controls \[[@CR44]\] as a result of increased activity-related energy expenditure (143 kcal/day) and decreased energy intake (128 kcal) \[[@CR45]\]. Several clinical trials have observed significant weight loss associated with the use of these drugs from 2.1 to 3.1 kg \[[@CR46], [@CR47]\]. Encouragingly, there are several ongoing and unreported preclinical, phase I/II trials investigating drugs utilising this dual mechanism of action \[[@CR48]\].

GLP-1/GIP Receptor Dual Agonists {#Sec19}
--------------------------------

Gastric inhibitory polypeptide (GIP) is a peptide hormone released by K-cells of the small intestine in response to food, which increases pancreatic insulin release. Combination therapy with GIP and GLP-1 enhances the incretin effect to improve dysglycaemia through increased prandial insulin secretion, reducing postprandial glycaemic excursions. However, GLP-1 and GIP demonstrate opposing actions on glucagon secretion. Whilst GIP stimulates glucagon secretion in low glucose environments, GLP-1 inhibits glucagon secretion in euglycaemia or hyperglycaemia \[[@CR49]\]. This effect has limited the use and production of GIP analogues as they may potentiate the diabetogenic glucagon effect through augmented gluconeogenesis and glycogenolysis. However, GIP was combined with a GLP-1 receptor agonist to counter the potential obesogenic effect of GIP with the anorectic effect of GLP-1 \[[@CR38]\].

Human studies have demonstrated good outcomes for weight reduction in people with (− 2.62 kg) and without (− 5.09 kg) T2D over 4 weeks compared with placebo \[[@CR50]\]. Similarly, a weight loss of 1.67% total body weight over 12 weeks was associated with the use of the dual GLP-1/GIP agonist NNC0090-2746 \[[@CR51]\]. Promising results have been observed for the GLP-1/GIP agonist LY3298176 in overweight or obese people with T2D, noting a weight loss between 0.9 and 11.3 kg in participants using the dual agent compared with 0.4 kg and 2.7 kg in those using placebo or dulaglutide respectively \[[@CR52]\]. Further preclinical and clinical trials utilising these dual agonists are ongoing, though results are unpublished at the time of writing \[[@CR48]\].

GLP-1/GIP/Glucagon Receptor Triple Agonists {#Sec20}
-------------------------------------------

Unimolecular triple agonists pose the greatest potential with respect to weight loss. A synergistic action in which glucagon receptor activation enhances energy expenditure whilst GLP-1 receptor agonists reduce calorie intake and both GLP-1/GIP potentiate the incretin effect to modulate the diabetogenic effect of glucagon agonists. Two triple agonists are currently in early stages of clinical trials with no yet published clinical trial data \[[@CR48]\]. However, preclinical studies of these drugs demonstrate supportive results in rodent and mice models \[[@CR53]--[@CR55]\], and we await further clinical trial data with anticipation.

Sodium-Glucose Co-Transporter-2 Inhibitors {#Sec21}
------------------------------------------

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are currently licensed for the treatment of T2D, though there is a growing body of evidence to support their use in cardiovascular \[[@CR56]\] and renal disease \[[@CR57]\]. These drugs block the SGLT-2 protein in the proximal convoluted tubule, thereby inducing a glucose-mediated osmotic diuresis and natriuresis, improving several metabolic measures \[[@CR58]\]. Interestingly, as a result of the enhanced glycosuria mediated by this class of medications, they are associated with an increased urinary loss of about 60--100 g of glucose (200--300 kcal) per day \[[@CR59]\]. One meta-analysis reported a mean weight loss of 2.1--2.7 kg associated with their use from phase III clinical trials in people with T2D \[[@CR60]\]. The EMA and FDA have approved several drugs in this class of medication for the treatment of T2D including dapagliflozin, empagliflozin, canagliflozin and ertugliflozin. However, none are yet approved by the EMA or FDA specifically for the treatment of obesity, though trials in obese people without T2D have shown promising results \[[@CR61]\].

Dapagliflozin {#Sec22}
-------------

Dapagliflozin (Forxiga) was the first SGLT-2 inhibitor to go to market, approved by the EMA in 2012 and the FDA in 2014 in the treatment of people with T2D. In people with T2D, dapagliflozin 10 mg daily is associated with a weight loss of 2.7--3.2 kg \[[@CR62], [@CR63]\]. In people without diabetes, some trials have explored dapagliflozin as a monotherapy or in combination with other weight loss agents have been explored. One study in people with prediabetes and a mean BMI of 30.3 kg/m^2^ received either dapagliflozin 10 mg or placebo for 12 weeks. The authors reported dapagliflozin use was associated with a 3.0 kg weight loss as well as improvements in several other metabolic markers \[[@CR64]\]. One trial explored the impact of combining dapagliflozin with the GLP-1 analogue exenatide in obese participants without diabetes, finding a mean weight loss 4.5 kg over 24 weeks \[[@CR65]\]. Importantly, these weight loss benefits were sustained with a reported weight loss of 5.7 kg over 52 weeks \[[@CR66]\].

Canagliflozin {#Sec23}
-------------

Canagliflozin (Invokana) was approved for use in people with T2D by the EMA and the FDA in 2013. In people with diabetes, canagliflozin induces additional weight loss of 2.5--4.0 kg \[[@CR67], [@CR68]\]. Canagliflozin has been trialed in a phase IIb study in overweight and obese subjects without T2D. Over a 12-week study, the authors reported a mean weight loss of 1.9 kg, 2.8 kg and 2.4 kg with the use of 50 mg, 100 mg or 300 mg respectively \[[@CR69]\]. Subsequently, a further trial investigated the co-administration of canagliflozin and phentermine in obese patients without T2D. Over 26 weeks, participants using canagliflozin lost 1.9 kg compared with 4.1 kg in those using phentermine and 7.3 kg in participants using both drugs \[[@CR70]\].

Empagliflozin {#Sec24}
-------------

Empagliflozin (Jardiance) was approved for the treatment of people with T2D by the EMA and the FDA in 2014. The use of empagliflozin in addition to metformin or sulphonylurea is associated with weight loss of 2.1--2.5 kg \[[@CR71], [@CR72]\]. We are not aware of any trial exploring the effect of empagliflozin on body weight in people without T2D at the time of writing.

Ertugliflozin {#Sec25}
-------------

Ertugliflozin (Steglatro) is the most recent SGLT-2 inhibitor to come to the market, with approval for use in people with T2D received from the EMA in 2018 and the FDA in 2017. A weight loss of 2.7--3.7 kg over 52 weeks has been associated with its use in people with T2D \[[@CR73], [@CR74]\]. To our knowledge, at the time of writing there are no trials exploring weight loss in people without T2D.

Other SGLT-2 Inhibitors {#Sec26}
-----------------------

One trial explored the use of the SGLT-2 inhibitors remogliflozin and sergliflozin compared with placebo controls in obese people without co-morbid diabetes over 8 weeks. The authors reported that in people using remogliflozin there was a 7.6 kg weight loss and 6.1 kg weight loss in those using sergliflozin compared with 5.1 kg weight loss in placebo controls \[[@CR75]\].

The clinical trials reporting on the impact of SGLT-2 inhibitors for weight loss in people with or without T2D are presented in Table [3](#Tab3){ref-type="table"}.Table 3Effect of SGLT-2 inhibitors on weight loss in people with and without T2DDrugApproval (year)Weight loss in people with diabetesWeight loss in people without diabetesDapagliflozinEMA (2012); FDA (2014)3.2 kg over 24 weeks \[[@CR58]\]Dapagliflozin: 3.0 kg (12 weeks) \[[@CR59]\]Dapagliflozin + exenatide: 5.7 kg (52 weeks) \[[@CR61]\]CanagliflozinEMA (2013); FDA (2013)2.5--4.0 kg \[[@CR63], [@CR64]\]Canagliflozin: 1.9 kg (50 mg); 2.8 kg (100 mg) and 2.4 kg (300 mg) \[[@CR65]\]EmpagliflozinEMA (2014); FDA (2014)2.1--2.5 kg over 24--104 weeks \[[@CR67], [@CR68]\]NoneErtugliflozinEMA (2018); FDA (2017)2.7--3.7 kg over 52 weeks \[[@CR69], [@CR70]\]NonePresents the observed weight loss with each of the approved SGLT-2 inhibitors in people with and without T2D

Other Emerging Therapeutic Targets {#Sec27}
==================================

Amylin Mimetics {#Sec28}
---------------

Amylin is a neuroendocrine peptide co-secreted by pancreatic β-cells postprandially with insulin and acts to inhibit glucagon secretion, reduce gastric emptying and centrally induce satiety \[[@CR76]\]. The amylin analogue pramlintide was licensed by the FDA in 2005 for patients with insulin-treated diabetes. Early studies reported that pramlintide use in people with insulin-treated diabetes is associated with improved glycaemic control and may support weight loss by reducing food intake \[[@CR77]\]. A subsequent trial in obese patients with either non-insulin treated T2D or without T2D found an additional mean weight loss of 3.7 kg versus placebo \[[@CR78]\]. Co-administration of pramlintide with either the sympathomimetic sibutramine or phentermine was observed to result in 9.2 kg weight loss compared with placebo over 24 weeks, whereas pramlintide monotherapy resulted in just 1.5 kg additional weight loss \[[@CR79]\]. However, development of these combination therapies was discontinued following commercial reassessment. Subsequently, a second-generation amylin analogue, davalintide, was developed and completed phase II trials. However, results were disappointing with weight loss comparable to pramlintide and inferior compared with pramlintide/metreleptin, also resulting in its discontinuation in its development \[[@CR80]\]. To further enhance the effect of amylin mimetics, preclinical studies have trialed these drugs in combination with calcitonin-receptor agonists as the amylin receptor consists of calcitonin receptor and activity-modifying proteins, thereby enhancing binding and activation of the amylin receptors \[[@CR81]\]. Whilst these preclinical studies show some promise \[[@CR82]\], human clinical trials are awaited.

Leptin Analogues {#Sec29}
----------------

Leptin is a 167 amino acid secreted by white adipose tissue, which promotes satiety and increases energy expenditure via stimulation of hypothalamic POMC neurons and inhibition of neuropeptide Y neurons. Overfeeding and high total body fat stimulate release of leptin, whilst the fasting state and low-fat stores inhibit leptin secretion \[[@CR83]\]. People with leptin gene mutations are obese secondary to pronounced hyperphagia \[[@CR84]\], and satiety and body weight can be regulated in people with these genetic mutations with leptin treatment \[[@CR85]\]. As such, there is a good rationale for leptin analogues in the treatment of obesity.

Metreleptin is a once daily subcutaneously administered leptin analogue approved by the FDA in 2014 for use in people with leptin deficiency or congenital/acquired lipodystrophy, with good clinical results in these conditions \[[@CR86]\]. Whilst metreleptin monotherapy supports weight loss in obese individuals, it is not clinically meaningful with a mean 1.5 kg additional weight loss over 24 weeks noted in a previous trial \[[@CR87]\]. To enhance the effect of leptin analogues, amylin mimetics such as pramlintide have been used in combination with metreleptin. One study found that use of the pramlintide/metreleptin combination resulted in 11.5 kg weight loss over 20 weeks compared with 7.4 kg and 7.9 kg weight loss respectively in participants receiving either metreleptin or pramlintide monotherapy \[[@CR88]\]. Unfortunately, the development of the combination therapy was discontinued in 2011 following commercial reassessment.

Ghrelin Vaccines and Antagonists {#Sec30}
--------------------------------

Ghrelin is the only known orexigenic peptide hormone and is secreted by the stomach and proximal small intestine. Conversely to the hormone leptin, ghrelin stimulates neuropeptide Y neurons and inhibits hypothalamic POMC neurons \[[@CR89]\]. As ghrelin induces hunger, inhibition of the ghrelin receptor represents an attractive therapeutic target in obesity. Ghrelin receptor antagonists and vaccines have shown promise with reduced food intake and body weight in pre-clinical studies \[[@CR90], [@CR91]\]. However, results in human trials are less favourable with no difference in weight between obese patients receiving ghrelin immunisation over 20 weeks, with both active and control groups losing 3.6 kg weight \[[@CR92]\]. We were unable to identify any current clinical trials exploring ghrelin antagonism under progress, though recently ghrelin receptor inverse agonists have been successfully profiled in humans \[[@CR93]\].

Neuropeptide Y Inhibitors {#Sec31}
-------------------------

Neuropeptide Y (NPY) neurons inhibit the appetite-suppressing POMC neurons and stimulate the release of appetite-inducing peptides such as orexin and melanin-concentrating hormone, making their inhibition an attractive therapeutic target in obesity. The first clinical trials to explore this mechanism used the NPY-antagonist MK-0557; however, results were disappointing with an additional annual weight loss of just 1.1 kg compared with placebo \[[@CR94]\]. Whilst early clinical studies of the NPY antagonist velneperit were encouraging with a reported additional 2.8 kg weight loss compared with placebo over 16 weeks \[[@CR95]\], subsequent phase IIb studies were disappointing and studies were discontinued. Further trials exploring the combination of the NPY inhibitor and orlistat were also disappointing and have been discontinued \[[@CR96]\].

Melanocortin-4 Receptor Agonists {#Sec32}
--------------------------------

Melanocortin receptors such as the melanocortin-4 receptor (MC4R) are stimulated by POMC-derived melanocortin peptides within the hypothalamus to suppress appetite. This is typically in response to POMC stimulation by hormones such as leptin. Conversely, POMC neurons are inhibited by NPY or ghrelin as discussed above. Therefore, drugs that enhance MC4R action should modulate food intake centrally to improve weight loss. Whilst mutations of the MC4R are a rare genetic cause of obesity, the treatment of two people with POMC deficiency with the MC4R agonist setmelanotide previously resulted in massive weight loss of 51.0 kg and 20.5 kg over 42 and 12 weeks respectively \[[@CR97]\], highlighting the potential of this mechanism to support weight loss in obesity. One phase IIb clinical trial administered setmelanotide to obese participants with heterozygous MC4R deficiency and obese controls over 28 days, observing a placebo-adjusted weight loss of 2.6 kg and 4.0 kg respectively \[[@CR98]\]. There are ongoing phase 2 and 3 trials using setmelanotide to further investigate the role of these medications in obesity \[[@CR99], [@CR100]\].

Cannabinoid Type-1 Receptor Antagonists {#Sec33}
---------------------------------------

The cannabinoid neurotransmitter system also affects the central control of appetite, with cannabinoid-1 receptor agonists increasing appetite and antagonists suppressing appetite \[[@CR101]\]. Therefore, cannabinoid receptor antagonists represent a further therapeutic option in the treatment of obesity. The first cannabanoid-1 receptor antagonist to enter clinical trials was rimonabant, which showed excellent weight loss outcomes with an additional mean weight loss of 4.7 kg \[[@CR102]\]. Moreover, rimonabant use was associated with several improved metabolic markers including glycaemic and lipid control \[[@CR103]\]. Whilst initially approved in the European market in 2006, the drug was later withdrawn in 2009 because of the increased risk of severe mood disorders and suicide \[[@CR104]\]. Whilst there is movement to design cannabanoid-1 receptor antagonists that are less hydrophobic to reduce blood-brain barrier penetration and therefore psychiatric side effects \[[@CR105]\], we are not aware of any ongoing clinical trials yet.

Conclusions {#Sec34}
===========

As our understanding of obesity and the associated hormonal changes continues to improve, further drug developments and therapies will be introduced. Currently, evidence is lacking to introduce many of these therapies into routine practice, though early results are promising. Within the rapidly developing world of diabetes pharmacotherapy, an increasing number of drug targets have been identified and these drugs are often associated with clinically significant weight loss. In this article we have highlighted important clinical trial data that support the pharmacotherapy of obesity. However, an important limitation is the omission of real-world data, which are often different from clinical trial results, partly because of varying patient populations. As further clinical trials continue, it is anticipated that more drugs will be approved for use in people with obesity to support weight loss before often riskier interventions such as bariatric surgery are required.
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